Physicians

Departments / Divisions

• Radiology / Chest Radiology
• Pathology
• Pharmacology & Cancer Biology

Address
DUMC 3808
Durham, NC 27710

Appointment Telephone
919-684-2711

Office Telephone
919-684-7311

Fax Telephone
919-684-7168

Training

• MD, University of Maryland School of Medicine, 1985

Residency

• Radiology, Brigham and Women's Hospital (Massachusetts), 1985-1990

Fellowship

• Thoracic Imaging, Brigham and Women's Hospital (Massachusetts), 1989-1990

Clinical Interests
General thoracic imaging, PET imaging of the thorax, interventional procedures in the thorax, biomarkers, early detection of cancer

Research Interests

There are numerous ongoing clinical studies primarily focused on the early detection of lung cancer.

The basic science investigations in our laboratory concentration on three fundamental translational areas,

1) Development of molecular imaging probes - We use several different approaches, including phage display, and in collaboration with our colleagues in the Chemistry Department, a mass spectrometry based method. These efforts are to develop novel imaging probes that characterize and phenotype tumors.

2) Discovery of novel lung cancer biomarkers - We explored the use of proteomics, autoantibodies, and genomics to discover blood and tissue biomarkers for early cancer detection and phenotyping of lung cancer.

3) Host response to cancer - We study the native immune response to tumors as this may provide cues to relevant diagnostic and therapeutic targets. Most recently we have focused on intratumoral lymphocytes and their specific tumor antigens.

 

Industry Relationships and Collaborations (What's this?)

This faculty member has no reported relationships with industry.

Representative Publications
Birchard, KR; Hoang, JK; Herndon, JE; Patz, EF. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer. 2009;115:581-586. (2009) Abstract

Gottlin, EB; Xiangrong Guan, ; Pegram, C; Cannedy, A; Campa, MJ; Patz, EF. Isolation of novel EGFR-specific VHH domains. Journal of Biomolecular Screening. 2009;14:77-85. (2009) Abstract

Berghmans, T; Dusart, M; Paesmans, M; Hossein-Foucher, C; Buvat, I; Castaigne, C; Scherpereel, A; Mascaux, C; Moreau, M; Roelandts, M; Alard, S; Meert, AP; Patz, EF; Lafitte, JJ; Sculier, JP; European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Journal of Thoracic Oncology. 2008;3:6-12. (2008) Abstract

Hoang, JK; Hoagland, LF; Coleman, RE; Coan, AD; Herndon, JE; Patz, EF. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. Journal of Clinical Oncology. 2008;26:1459-1464. (2008) Abstract

Hopper, ED; Roulhac, PL; Campa, MJ; Patz, EF; Fitzgerald, MC. Throughput and efficiency of a mass spectrometry-based screening assay for protein-ligand binding detection. Journal of the American Society for Mass Spectrometry. 2008;19:1303-1311. (2008) Abstract

Schultz, EM; Sanders, GD; Trotter, PR; Patz, EF; Silvestri, GA; Owens, DK; Gould, MK. Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. Thorax. 2008;63:335-341. (2008) Abstract

Hoagland, LF; Campa, MJ; Gottlin, EB; Herndon, JE; Patz, EF. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer. 2007;110:2260-2268. (2007) Abstract

Patz, EF; Campa, MJ; Gottlin, EB; Kusmartseva, I; Guan, XR; Herndon, JE. Panel of serum biomarkers for the diagnosis of lung cancer. Journal of Clinical Oncology. 2007;25:5578-5583. (2007) Abstract

Patz, EF. Integration of biomarkers and imaging. Journal of Thoracic Oncology. 2006;1:78-80. (2006) Abstract

Patz, EF. Lung cancer screening, overdiagnosis bias, and reevaluation of the Mayo Lung Project. Journal of National Cancer Institute. 2006;98:724-725. (2006) Abstract

Petersen, RP; Campa, MJ; Sperlazza, J; Conlon, D; Joshi, MB; Harpole, DH; Patz, EF. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006;107:2866-2872. (2006) Abstract

Howard, BA; Furumai, R; Campa, MJ; Rabbani, ZN; Vujaskovic, Z; Wang, XF; Patz, EF. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Research. 2005;65:8853-8860. (2005) Abstract

MacMahon, H; Austin, JH; Gamsu, G; Herold, CJ; Jett, JR; Naidich, DP; Patz, EF; Swensen, SJ; Fleischner Society. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology. 2005;237:395-400. (2005) Abstract

Howard, BA; Zheng, Z; Campa, MJ; Wang, MZ; Sharma, A; Haura, E; Herndon, JE; Fitzgerald, MC; Bepler, G; Patz, EF. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer. 2004;46:313-323. (2004) Abstract

Patz, EF; Swensen, SJ; Herndon, JE. Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations. Journal of Clinical Oncology. 2004;22:2202-2206. (2004) Abstract

Suber, RL; Flanders, VL; Campa, MJ; Patz, EF. Accentuation of differentially expressed proteins using phage technology. Analytical Biochemistry. 2004;333:351-357. (2004) Abstract

Wang, MZ; Shetty, JT; Howard, BA; Campa, MJ; Patz, EF; Fitzgerald, MC. Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate. Analytical Chemistry. 2004;76:4343-4348. (2004) Abstract

Campa, MJ; Wang, MZ; Howard, B; Fitzgerald, MC; Patz, EF. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Research. 2003;63:1652-1656. (2003) Abstract

Campa, MJ; Serlin, SB; Patz, EF. Development of novel tumor imaging agents with phage-display combinatorial peptide libraries. Academic Radiology. 2002;9:927-932. (2002) Abstract

Grannis, FW. Potential conflict of interest in AJRCCM. American Journal of Respiratory and Critical Care Medicine. 2002;166:1608. (2002) Abstract

Heyneman, LE; Patz, EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer. 2002;38:261-266. (2002) Abstract

Marom, EM; Erasmus, JJ; Pass, HI; Patz, EF. The role of imaging in malignant pleural mesothelioma. Seminars in Oncology. 2002;29:26-35. (2002) Abstract

Marom, EM; Sarvis, S; Herndon, JE; Patz, EF. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology. 2002;223:453-459. (2002) Abstract

Aloia, T; Bepler, G; Harpole, D; Goodman, PC; McAdams, HP; Erasmus, JJ; Herndon, JE; Patz, EF. Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities. Cancer Epidemiology: the international journal of cancer epidemiology, detection and prevention. 2001;25:336-343. (2001) Abstract

Crotty, E; Patz, EF. FDG-PET imaging in patients with paraneoplastic syndromes and suspected small cell lung cancer. Journal of Thoracic Imaging. 2001;16:89-93. (2001) Abstract

Dammas, S; Patz, EF; Goodman, PC. Identification of small lung nodules at autopsy: implications for lung cancer screening and overdiagnosis bias. Lung Cancer. 2001;33:11-16. (2001) Abstract

Heyneman, LE; Herndon, JE; Goodman, PC; Patz, EF. Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening. Cancer. 2001;92:3051-3055. (2001) Abstract

Marom, EM; Aloia, TA; Moore, MB; Hara, M; Herndon, JE; Harpole, DH; Goodman, PC; Patz, EF. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001;33:99-107. (2001) Abstract

Patz, EF; Black, WC; Goodman, PC. CT screening for lung cancer: not ready for routine practice. Radiology. 2001;221:587-591. (2001) Abstract

Patz, EF; Goodman, PC. Low-dose spiral computed tomography screening for lung cancer: not ready for prime time. American Journal of Respiratory and Critical Care Medicine. 2001;163:813-814. (2001) Abstract

Patz, EF; Goodman, PC; Bepler, G. Screening for lung cancer. New England Journal of Medicine. 2000;343:1627-1633. (2000) Abstract

Patz, EF; McAdams, HP; Erasmus, JJ; Goodman, PC; Culhane, DK; Gilkeson, RC; Herndon, J. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest. 1998;113:1305-1311. (1998) Abstract

Campa, MJ; Schreiber, G; Bepler, G; Bishop, MJ; McNutt, RW; Chang, KJ; Patz, EF. Characterization of delta opioid receptors in lung cancer using a novel nonpeptidic ligand. Cancer Research. 1996;56:1695-1701. (1996) Abstract